Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 1:06 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 7,063 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer, Breast Neoplasms Clear all
Completed Phase 1 Interventional

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

NCT02996825
View directory record Official record
Conditions
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacological Study
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Duarte, California • Upland, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 2, 2026, 1:06 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Nuevo Amanecer II: Translating a Stress Management Program for Latinas

NCT02931552
View directory record Official record
Conditions
Breast Neoplasms, Psychology, Social
Interventions
Nuevo Amancer-II Stress Management Program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Multiple Locations, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Nov 2, 2026, 1:06 AM EST
Not listed Not applicable Interventional

Weight Gain Prevention for Breast Cancer Survivors

NCT00533338
View directory record Official record
Conditions
Breast Cancer
Interventions
Weight Gain Prevention Program, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Nov 2, 2026, 1:06 AM EST
Completed Phase 1 Interventional

A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer

NCT01095848
View directory record Official record
Conditions
Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions
DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
Biological
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Buffalo, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Nov 2, 2026, 1:06 AM EST
Completed Phase 2 Interventional Results available

Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery

NCT03624478
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8
Interventions
Hypofractionated Radiation Therapy
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 2, 2026, 1:06 AM EST
Completed Not applicable Interventional

Feasibility of High Levels of Energy Expenditure From Physical Activity for Breast Cancer Survivors

NCT02963740
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Supervised Exercise, Home-based Exercise, Group Phone Calls, Diet
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Up to 71 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Nov 2, 2026, 1:06 AM EST
Completed Not applicable Interventional

Integrative Approaches to Cancer Survivorship: Project 3

NCT03479385
View directory record Official record
Conditions
Breast Cancer
Interventions
Integrative Medicine Intervention, Health Education Intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Nov 2, 2026, 1:06 AM EST
Completed Not applicable Interventional

Genetic Testing for All Breast Cancer Patients (GET FACTS)

NCT04245176
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Genetic Testing
Interventions
Standard Genetic Counseling, Quantitative Genetic Counseling
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 2, 2026, 1:06 AM EST
Completed No phase listed Observational Results available

Breast Cup Immobilization Device II (GCC 1047)

NCT01704547
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Nov 2, 2026, 1:06 AM EST
Recruiting Phase 2 Interventional

Pioglitazone Therapy Targeting Fatigue in Breast Cancer

NCT05013255
View directory record Official record
Conditions
Breast Cancer, Muscle Fatigue
Interventions
Pioglitazone 15mg, Pioglitazone 30 mg
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Nov 2, 2026, 1:06 AM EST
Completed No phase listed Observational

Ultrasound Targeting for the Lumpectomy Cavity

NCT00583843
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Ultrasound
Procedure
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Nov 2, 2026, 1:06 AM EST
Recruiting Phase 2 Interventional

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

NCT04899908
View directory record Official record
Conditions
Brain Cancer, Brain Metastases, Melanoma, Lung Cancer, Breast Cancer, HER2-positive Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, SRS, SRT, Whole Brain Radiation, Stereotactic Radiation, AGuIX, Nanoparticle, Cystic, Brain Tumor
Interventions
Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo
Radiation · Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 2, 2026, 1:06 AM EST
Completed Not applicable Interventional Results available

Radiofrequency Chip for Localization of Non-Palpable Breast Lesions

NCT03684408
View directory record Official record
Conditions
Breast Tumor
Interventions
RFID Localization, Wire Localization, RFID and Wire Localization
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Nov 2, 2026, 1:06 AM EST
Withdrawn No phase listed Observational

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

NCT00873808
View directory record Official record
Conditions
Breast Cancer
Interventions
clodronate disodium, demeclocycline hydrochloride, ibandronate sodium, tetracycline hydrochloride, zoledronic acid, laboratory biomarker analysis, adjuvant therapy, computed tomography, dual x-ray absorptiometry
Drug · Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Nov 2, 2026, 1:06 AM EST
Completed Not applicable Interventional Results available

Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast

NCT00496808
View directory record Official record
Conditions
Ductal Carcinoma In Situ
Interventions
Herceptin (Trastuzumab)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Nov 2, 2026, 1:06 AM EST
Completed Phase 2 Interventional Results available

Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients

NCT00206518
View directory record Official record
Conditions
Breast Cancer
Interventions
Taxotere/Docetaxel, Adriamycin/Cytoxan, doxorubicin
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older · Female only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Nov 2, 2026, 1:06 AM EST
Active, not recruiting No phase listed Observational

Diet, Hepcidin, and Chemotherapy RDI

NCT06483997
View directory record Official record
Conditions
Breast Cancer Female, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Endometrial Cancer, Gynecologic Cancer
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
21 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 2, 2026, 1:06 AM EST
Completed Phase 2 Interventional Results available

Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer

NCT01299038
View directory record Official record
Conditions
Breast Cancer
Interventions
rosuvastatin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Nov 2, 2026, 1:06 AM EST
Completed Not applicable Interventional

Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients

NCT04604158
View directory record Official record
Conditions
Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Glioblastoma, Prostate Cancer, Gynecologic Cancer, Colorectal Cancer, Sarcoma, Kidney Cancer, Bladder Cancer, Lymphoma, Leukemia, Head and Neck Cancer, Pancreas Cancer, Multiple Myeloma, Anxiety, Social Isolation, Stress, Loneliness, Melanoma, Uterine Cancer
Interventions
Elly Mobile Phone Application
Behavioral
Lead sponsor
Gillian Gresham
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Nov 2, 2026, 1:06 AM EST
Terminated Phase 2 Interventional Results available

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer

NCT00088985
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Nov 2, 2026, 1:06 AM EST
Active, not recruiting No phase listed Observational

IORT-Breast at Medical Center Navicent Health

NCT04595435
View directory record Official record
Conditions
Breast Cancer Female, Early-stage Breast Cancer
Interventions
Lumpectomy, Intraoperative Radiation Therapy
Procedure · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
1
States / cities
Macon, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 2, 2026, 1:06 AM EST
Completed Phase 2 Interventional Results available

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

NCT00733408
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
17
States / cities
Anchorage, Alaska • Yuma, Arizona • Lewiston, Idaho + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Nov 2, 2026, 1:06 AM EST
Active, not recruiting Phase 2 Interventional

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

NCT03449108
View directory record Official record
Conditions
Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Platinum-Resistant Ovarian Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Osteosarcoma, Recurrent Ovarian Carcinoma, Refractory Osteosarcoma, Soft Tissue Sarcoma, Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Triple Negative Breast Cancer
Interventions
Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1, Cyclophosphamide, Fludarabine, Ipilimumab, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 2, 2026, 1:06 AM EST
Recruiting Phase 3 Interventional

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

NCT05929768
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Paclitaxel, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
955
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 654 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Nov 2, 2026, 1:06 AM EST